Transplacental transfer and distribution of pravastatin

被引:70
作者
Nanovskaya, Tatiana N. [1 ]
Patrikeeva, Svetlana L. [1 ]
Paul, Jonathan [1 ]
Costantine, Maged M. [1 ]
Hankins, Gary D. V. [1 ]
Ahmed, Mahmoud S. [1 ]
机构
[1] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA
关键词
pravastatin; preeclampsia; pregnancy; transplacental transfer; CANCER RESISTANCE PROTEIN; COA REDUCTASE INHIBITORS; CORONARY-HEART-DISEASE; MEMBRANE-VESICLES; P-GLYCOPROTEIN; TRANSPORT; PREVENTION; PREGNANCY; EXPOSURE; OUTCOMES;
D O I
10.1016/j.ajog.2013.05.038
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The objective of the study was to determine the bidirectional transfer of pravastatin across the dually perfused term human placental lobule and its distribution between the tissue and maternal and fetal circuits. STUDY DESIGN: The transfer of pravastatin was determined in the maternal-to-fetal (n - 11) and fetal-to-maternal (n - 10) directions. Pravastatin was coperfused with its [H-3]-isotope and the marker compound antipyrine (20 mu g/mL) and its [C-14]-isotope. The concentration of pravastatin in the perfused tissue and the maternal and fetal circuits was determined using liquid scintillation spectrometry. Inside-out vesicles prepared from placental brush border membranes were utilized to investigate the role of efflux transporters in the transplacental transfer of pravastatin. RESULTS: Pravastatin was transferred from the maternal to the fetal circuit and vice versa. In the maternal-to-fetal direction, the distribution of pravastatin at the end of experiment was as follows: 14 +/- 5% of the drug was retained by the tissue, 68 +/- 5% remained in the maternal circuit, and 18 +/- 4% was transferred to the fetal circuit. The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 +/- 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 +/- 0.07, P < .01). Furthermore, pravastatin inhibited the adenosine triphosphate (ATP) e dependent uptake of the paclitaxel and estrone sulfate. CONCLUSION: The transfer of pravastatin across the dually perfused placental lobule suggests that fetal exposure to pravastatin is plausible. The higher transfer of pravastatin in the fetal-to-maternal direction than the reverse as well as its inhibition of the ATP-dependent uptake of [H-3]paclitaxel and [H-3]-estrone sulfate strongly suggest the involvement of efflux transporters in decreasing its transfer across the placenta and support pravastatin's favorable pharmacokinetic profile in pregnancy.
引用
收藏
页数:5
相关论文
共 26 条
[1]   Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1 [J].
Chen, CP ;
Mireles, RJ ;
Campbell, SD ;
Lin, J ;
Mills, JB ;
Xu, JHJ ;
Smolarek, TA .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) :537-546
[2]   Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women [J].
Costantine, Maged M. ;
Cleary, Kirsten .
OBSTETRICS AND GYNECOLOGY, 2013, 121 (02) :349-353
[3]  
Drugs.com, 1996, PRAV PREGN BREASTF W
[4]   Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins [J].
Edison, RJ ;
Muenke, M .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 131A (03) :287-298
[5]   Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions [J].
Elsby, Robert ;
Smith, Veronica ;
Fox, Lisa ;
Stresser, David ;
Butters, Caroline ;
Sharma, Pradeep ;
Surry, Dominic D. .
XENOBIOTICA, 2011, 41 (09) :764-783
[6]   Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors [J].
Hamelin, BA ;
Turgeon, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (01) :26-37
[7]   Clinical pharmacokinetics of pravastatin - Mechanisms of pharmacokinetic events [J].
Hatanaka, T .
CLINICAL PHARMACOKINETICS, 2000, 39 (06) :397-412
[8]   Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles [J].
Hemauer, Sarah J. ;
Patrikeeva, Svetlana L. ;
Nanovskaya, Tatiana N. ;
Hankins, Gary D. V. ;
Ahmed, Mahmoud S. .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (09) :1272-1278
[9]   Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin [J].
Hirano, M ;
Maeda, K ;
Hayashi, H ;
Kusuhara, H ;
Sugiyama, Y .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (02) :876-882
[10]  
Hosokawa A, 2003, CAN FAM PHYSICIAN, V49, P747